Total Payments
$803,515
2024 Payments
$102,694
Companies
66
Transactions
1,821
Medicare Patients
1,210
Medicare Billing
$176,571
Payment Breakdown by Category
Other$589,225 (73.3%)
Travel$114,014 (14.2%)
Consulting$56,955 (7.1%)
Food & Beverage$42,855 (5.3%)
Education$465.06 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $539,357 | 262 | 67.1% |
| Travel and Lodging | $114,014 | 434 | 14.2% |
| Consulting Fee | $56,955 | 21 | 7.1% |
| Honoraria | $49,868 | 31 | 6.2% |
| Food and Beverage | $42,855 | 1,066 | 5.3% |
| Education | $465.06 | 7 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $251,307 | 333 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $172,096 | 263 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $97,920 | 175 | $0 (2024) |
| Kyowa Kirin, Inc. | $64,733 | 72 | $0 (2024) |
| MDD US Operations, LLC | $60,817 | 87 | $0 (2024) |
| Lundbeck LLC | $54,706 | 106 | $0 (2020) |
| US WorldMeds, LLC | $44,988 | 165 | $0 (2020) |
| Acorda Therapeutics, Inc | $28,622 | 64 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $6,202 | 42 | $0 (2021) |
| Amneal Pharmaceuticals LLC | $5,193 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $102,694 | 204 | Teva Pharmaceuticals USA, Inc. ($71,033) |
| 2023 | $107,829 | 247 | Teva Pharmaceuticals USA, Inc. ($36,629) |
| 2022 | $98,740 | 191 | Teva Pharmaceuticals USA, Inc. ($77,846) |
| 2021 | $47,193 | 108 | MDD US Operations, LLC ($19,651) |
| 2020 | $23,406 | 82 | ACADIA Pharmaceuticals Inc ($7,572) |
| 2019 | $161,383 | 384 | Neurocrine Biosciences, Inc. ($63,652) |
| 2018 | $144,390 | 333 | Neurocrine Biosciences, Inc. ($78,321) |
| 2017 | $117,880 | 272 | ACADIA Pharmaceuticals Inc ($60,331) |
All Payment Transactions
1,821 individual payment records from CMS Open Payments — Page 1 of 73
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $40.25 | General |
| Category: Neurology | ||||||
| 12/16/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $0.29 | General |
| Category: Neurology | ||||||
| 12/12/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: NEUROLOGY | ||||||
| 12/10/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $130.35 | General |
| Category: Central Nervous System | ||||||
| 12/10/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,600.00 | General |
| Category: Central Nervous System | ||||||
| 12/05/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $88.86 | General |
| Category: Central Nervous System | ||||||
| 11/19/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: Rare Disease | ||||||
| 11/15/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $8.97 | General |
| Category: NEUROSCIENCE | ||||||
| 11/14/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $33.88 | General |
| Category: Genetic Disease | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: Neurology | ||||||
| 11/08/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $34.02 | General |
| Category: NEUROLOGY | ||||||
| 11/06/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/05/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $25.46 | General |
| Category: Neurology | ||||||
| 10/30/2024 | Grifols USA, LLC | Gamunex-C (Biological) | Food and Beverage | In-kind items and services | $25.01 | General |
| Category: Immunology and Neurology | ||||||
| 10/30/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $9.39 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/25/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: Immunology | ||||||
| 10/25/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/24/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: Neurology | ||||||
| 10/23/2024 | ABBVIE INC. | VYALEV (Drug), DUOPA | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: NEUROSCIENCE | ||||||
| 10/17/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: NEUROSCIENCE | ||||||
| 10/14/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $132.72 | General |
| Category: AMANTADINE | ||||||
| 10/14/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $26.55 | General |
| Category: Neurology | ||||||
| 10/12/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $134.13 | General |
| Category: Central Nervous System | ||||||
| 10/10/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $9.33 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 321 | 426 | $149,073 | $46,958 |
| 2022 | 6 | 276 | 380 | $132,006 | $40,853 |
| 2021 | 6 | 295 | 409 | $144,812 | $46,034 |
| 2020 | 5 | 318 | 414 | $153,310 | $42,725 |
Total Patients
1,210
Total Services
1,629
Medicare Billing
$176,571
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 130 | 193 | $66,585 | $22,815 | 34.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 54 | 54 | $26,406 | $8,632 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 51 | 60 | $15,420 | $4,988 | 32.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 52 | $15,600 | $4,719 | 30.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 28 | $16,324 | $3,701 | 22.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $6,208 | $1,789 | 28.8% |
| 95970 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | Office | 2023 | 17 | 23 | $2,530 | $314.38 | 12.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 129 | 195 | $67,275 | $22,666 | 33.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 46 | 46 | $22,494 | $7,133 | 31.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 25 | 25 | $14,575 | $3,775 | 25.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 46 | $11,822 | $3,680 | 31.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 44 | $13,200 | $3,304 | 25.0% |
| 95970 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | Office | 2022 | 15 | 24 | $2,640 | $294.60 | 11.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 129 | 196 | $67,620 | $24,305 | 35.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 45 | 45 | $21,953 | $6,808 | 31.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 40 | 40 | $23,320 | $6,257 | 26.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 38 | 73 | $21,900 | $5,890 | 26.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 27 | $6,939 | $2,439 | 35.1% |
| 95970 | Electronic analysis of implanted brain, spinal cord or peripheral stimulation device | Office | 2021 | 16 | 28 | $3,080 | $334.40 | 10.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 122 | 171 | $59,139 | $16,185 | 27.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 61 | 104 | $31,200 | $8,545 | 27.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 47 | 48 | $27,984 | $7,667 | 27.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 50 | 50 | $24,450 | $7,392 | 30.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 38 | 41 | $10,537 | $2,936 | 27.9% |
About Dr. Daniel Dees, M.D
Dr. Daniel Dees, M.D is a Neurology healthcare provider based in Mobile, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1700066677.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Dees, M.D has received a total of $803,515 in payments from pharmaceutical and medical device companies, with $102,694 received in 2024. These payments were reported across 1,821 transactions from 66 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($539,357).
As a Medicare-enrolled provider, Dees has provided services to 1,210 Medicare beneficiaries, totaling 1,629 services with total Medicare billing of $176,571. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Student in an Organized Health Care Education/Training Program
- Location Mobile, AL
- Active Since 11/08/2007
- Last Updated 02/22/2017
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1700066677
Products in Payments
- INGREZZA (Drug) $169,890
- AUSTEDO (Drug) $154,223
- NUPLAZID (Drug) $97,903
- Austedo XR (Drug) $91,481
- NORTHERA (Drug) $54,459
- Nourianz (Drug) $50,797
- APOKYN (Drug) $45,888
- Xadago (Drug) $30,521
- INBRIJA (Drug) $28,164
- NOURIANZ (Drug) $13,936
- Apokyn (Drug) $12,923
- MYOBLOC (Biological) $10,500
- KYNMOBI (Drug) $5,438
- SD809-HD (Drug) $3,799
- ACTIVA (Device) $3,078
- Neupro (Drug) $2,395
- GOCOVRI (Drug) $2,019
- RYTARY (Drug) $1,527
- BOTOX (Biological) $817.13
- SD809-TD (Drug) $804.54
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Mobile
Dr. Hayden Long, Md, MD
Neurology — Payments: $295,347
Neurology $295,347
Dr. Charles Markle, M.d, M.D
Neurology — Payments: $265,994
Neurology $265,994
Dean Naritoku, M.d, M.D
Neurology — Payments: $250,962
Neurology $250,962
Bassam Bassam, Md, MD
Neurology — Payments: $139,121
Neurology $139,121
Dr. Juan Ochoa, Md, MD
Neurology — Payments: $88,415
Neurology $88,415
Laura Minto, Md, MD
Neurology — Payments: $83,902
Neurology $83,902